Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on sensitive biological samples.
This rejection was revealed following a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson later explained that the United States was demanding access to genetic material for research and commercial purposes but was unwilling to share the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more negotiations to reach a agreement acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a similar situation in Kenya, where a high court halted a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
Since returning to office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to boost transparency and accountability.
According to statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery without any certainty that the final treatments would be available to our citizens if a new health crisis arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending systems already established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This system is intended to guarantee that when a country provides its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our American counterparts on how future collaboration could be arranged in a manner that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it recognised the official position, but suggested that negotiations must proceed since much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group added.
The halted deal emphasises the continuing debate between accepting vital foreign assistance and safeguarding national sovereignty in an ever more data-driven world.